How is Pfizer’s Covid vaccine trial going?

How is Pfizer's Covid vaccine trial going?

What the Financial Times wrote about the BioNTech and Pfizer anti Covid-19 vaccine


A coronavirus vaccine from Germany's BioNTech gave positive test results, generating immune defenses in the participants who were stronger than those of the average patient cured of Covid-19, according to preliminary data released by the company.

In a clinical study conducted with the pharmaceutical group Pfizer in the United States, 24 people aged 18 to 55 who received two doses of the vaccine had "significantly elevated" antibodies within four weeks of the first injection.

In total, 45 people involved in the study, with some receiving placebo and others receiving higher doses of the vaccine.

BioNTech, the first European company to release the results of the vaccine trial, is one of several companies that use messenger RNA (mRNA) technology to develop a vaccine – a faster process than traditional methods.

BioNTech's shares, listed on the Nasdaq in New York, rose by nearly 8 percent following the news of the trial results, while Pfizer's share price rose by a similar percentage.

Based on initial trial results, BioNTech and Pfizer are hoping to move to a larger trial in the United States, involving 30,000 participants in a matter of weeks, subject to regulatory approval.

Ugur Sahin, co-founder and CEO of BioNTech, told the Financial Times that the company is opting for a higher level of neutralizing antibody responses to increase the likelihood that vaccinated people won't spread the disease and won't contract it.

"If you don't know the level needed to control this virus, if you don't know the power of the enemy, you don't want the response to be too weak," he said.

BioNTech and Pfizer expect to be able to produce up to 100 m vaccine doses by the end of the year, and more than 1.2 billion doses by the end of 2021, depending on the required doses.

(Taken from the Eprcomunicazione foreign press review)


This is a machine translation from Italian language of a post published on Start Magazine at the URL https://www.startmag.it/innovazione/come-va-la-sperimentazione-del-vaccino-anti-covid-di-pfizer/ on Sat, 04 Jul 2020 07:15:34 +0000.